Lupin Expands Dabhasa Facility to Scale Peptide Manufacturing

Lupin Manufacturing Solutions (LMS), a global Contract Development and Manufacturing Organization (CDMO) and subsidiary of Lupin Limited, has announced the expansion of its Dabhasa manufacturing facility in India.

This brand-building move will position the company better in its peptide building-block platform and increase its CRDMO, which will be an essential move to expand the infrastructure to accommodate more sophisticated pharmaceutical solutions to the world.

The development of the infrastructure is the addition of a new block aimed at the growth of the capabilities of CRDMO, and two other special units focused on the production of peptides.

These upgrades will enable complex therapeutics that require complex development and flexible production to address the increased demand for complex therapeutics like peptides and biologic antibody-drug conjugates (ADCs).

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

Dr. Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions, emphasized, "As pharmaceutical innovation increasingly shifts toward complex modalities, building deep capabilities and execution excellence has become critical. This expansion underscores our commitment to building advanced, scalable capabilities that support complex development programs and reinforce our role in the global peptide ecosystem."

This growth will help LMS to provide high-quality peptide building blocks, including the use of protected amino acids, in a steady supply to satisfy the requirements of the innovators in biopharma.

As the global drug development focus has moved towards molecular complexity, LMS is still determined to offer integrated solutions in drug substances, complex chemistry, and advanced modalities.